Amphastar Pharmaceuticals Inc (AMPH) CEO Jack Y. Zhang Sells 66,757 Shares

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) CEO Jack Y. Zhang sold 66,757 shares of the company’s stock in a transaction dated Tuesday, December 11th. The shares were sold at an average price of $21.47, for a total value of $1,433,272.79. Following the completion of the transaction, the chief executive officer now owns 2,115,894 shares in the company, valued at approximately $45,428,244.18. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

NASDAQ:AMPH traded down $0.21 during mid-day trading on Thursday, reaching $20.90. The stock had a trading volume of 151,562 shares, compared to its average volume of 202,211. Amphastar Pharmaceuticals Inc has a fifty-two week low of $14.40 and a fifty-two week high of $22.74. The company has a market capitalization of $979.59 million, a P/E ratio of 55.00 and a beta of 1.42. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.34 and a current ratio of 2.02.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Thursday, November 8th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. Amphastar Pharmaceuticals had a positive return on equity of 2.80% and a negative net margin of 2.33%. The firm had revenue of $75.54 million for the quarter, compared to the consensus estimate of $76.84 million. During the same quarter in the prior year, the company posted $0.07 earnings per share. The firm’s revenue was up 30.5% on a year-over-year basis. As a group, sell-side analysts forecast that Amphastar Pharmaceuticals Inc will post -0.06 earnings per share for the current fiscal year.

A number of equities analysts have recently weighed in on the company. BidaskClub upgraded Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 18th. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. ValuEngine upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 17th. Needham & Company LLC set a $25.00 price objective on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, November 9th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $26.00 price objective on shares of Amphastar Pharmaceuticals in a report on Wednesday, November 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $23.60.

A number of large investors have recently added to or reduced their stakes in AMPH. Principal Financial Group Inc. increased its holdings in Amphastar Pharmaceuticals by 2.2% in the first quarter. Principal Financial Group Inc. now owns 273,428 shares of the company’s stock worth $5,127,000 after buying an additional 5,789 shares during the last quarter. State of Wisconsin Investment Board boosted its position in Amphastar Pharmaceuticals by 29.3% during the second quarter. State of Wisconsin Investment Board now owns 36,200 shares of the company’s stock worth $552,000 after purchasing an additional 8,200 shares during the period. Sei Investments Co. boosted its position in Amphastar Pharmaceuticals by 4.9% during the second quarter. Sei Investments Co. now owns 67,934 shares of the company’s stock worth $1,037,000 after purchasing an additional 3,193 shares during the period. Engineers Gate Manager LP bought a new stake in Amphastar Pharmaceuticals during the second quarter worth approximately $387,000. Finally, Rhumbline Advisers boosted its position in Amphastar Pharmaceuticals by 7.4% during the second quarter. Rhumbline Advisers now owns 89,343 shares of the company’s stock worth $1,363,000 after purchasing an additional 6,191 shares during the period. Hedge funds and other institutional investors own 44.74% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by WKRB News and is the property of of WKRB News. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.wkrb13.com/2018/12/14/amphastar-pharmaceuticals-inc-amph-ceo-jack-y-zhang-sells-66757-shares.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Read More: Intrinsic Value and Stock Selection

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply